Personalized treatment for low-risk triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new personalized treatment approach (mRNA-lncRNA model) for people with low-risk, early-stage triple-negative breast cancer who have already had surgery. It aims to see if a less intense treatment can work just as well as standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman aged 18 to 70.
- Have early-stage triple-negative breast cancer after full surgical removal.
- Your tumor must be classified as 'low-risk' by a special genetic test (mRNA-lncRNA model).
- Be in generally good health with normal blood counts, liver, and kidney function.
- Not have received chemotherapy, radiation, or targeted therapy before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
This trial tests a personalized cancer vaccine for triple negative breast cancer. It is given alongside standard chemotherapy and immunotherapy to help your immune system fight the cancer.
This trial studies patterns of microRNA (tiny gene-regulating molecules) in women with triple-negative breast cancer. By comparing these microRNA profiles, the study hopes to better understand the disease and potentially guide future treatment choices.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.